Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On November 10, 2025, the company’s compensation committee granted a total of 16,463 RSUs, equivalent to 214,019 underlying shares, to 143 employees, representing approximately 0.01% of the total issued shares. The RSUs will vest over four years, with specific conditions for accelerated vesting. This move is part of BeOne’s strategy to incentivize its workforce and align their interests with the company’s growth objectives.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$222.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 5,439,124
Technical Sentiment Signal: Buy
Current Market Cap: HK$316B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.